Moreover, a study demonstrated that PX-866, an irreversible small molecule panisoform inhibitor of PI3K, can be safely used in combination with a modified dose of vemurafenib in the treatment of patients with advanced BRAF V600-mutated cancers [317]. Here, PIK3CA is linked to cancer.